Galapagos CEO Upbeat Despite Filgotinib Upset In US
Focus Now On Jyseleca Launches In Europe
Onno van de Stolpe has told Scrip it will take time to win investor confidence back after more disappointing news about the JAK inhibitor but Galapagos has "the pipeline and the cash in the organization to do so."
